The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     
 


Published online June 17, 2009
The Journal of Immunology, 2009, doi:10.4049/jimmunol.0804154
Copyright © 2009 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jimmunol.0804154v1
183/1/75    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Esensten, J. H.
Right arrow Articles by Bluestone, J. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esensten, J. H.
Right arrow Articles by Bluestone, J. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
Medline Plus Health Information
*Diabetes Type 1

T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function

Jonathan H. Esensten*, Michael R. Lee*, Laurie H. Glimcher{dagger} and Jeffrey A. Bluestone*

*Diabetes Center and the Department of Medicine, University of California, San Francisco, CA 94143; and {dagger}Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115

The transcription factor T-bet (Tbx21) is critical for Th1 polarization of CD4+ T cells. Genetic deletion of Tbx21 can cause either exacerbation or attenuation of different autoimmune diseases in animal models. In the nonobese diabetic (NOD) mouse, genetic deletion of the Ifng or the Il12b (IL-12p40) genes, which are both critical Th1 cytokines, does not reduce the incidence of autoimmune diabetes. These results suggest that autoimmune diabetes in the NOD may not be a Th1-driven disease. However, we report that Tbx21 deficiency in the NOD mouse completely blocks insulitis and diabetes due to defects both in the initiation of the anti->islet immune response and in the function of CD4+ effector T cells. We find defective priming of naive islet-reactive T cells by the innate immune system in Tbx21–/– animals. By contrast to naive cells, activated islet-reactive BDC2.5 TCR-transgenic T cells do not require Tbx21 in recipient animals for efficient adoptive transfer of diabetes. However, when these BDC2.5 TCR-transgenic effector cells lack Tbx21, they are less effective at entering the pancreas and promoting diabetes than Tbx21+/+ cells. Tbx21–/– regulatory T cells function normally in vitro and diabetes can be restored in Tbx21–/– mice by reducing regulatory T cell numbers. Thus, the absence of diabetes in the NOD.Tbx21–/– is due to intrinsic defects in both T cells and cells of the innate immune system paired with the relative preservation of regulatory T cell function.

Address correspondence and reprint requests to Dr. Jeffrey A. Bluestone, Diabetes Center, University of California, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143. E-mail address: jbluest{at}diabetes.ucsf.edu.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.